Clinical Trial Update: Gene Therapy for ADA-SCID [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 gene therapy trial for ADA-SCID conducted by IRCCS San Raffaele has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• ADA-SCID gene therapy

Snippet

Sponsor: IRCCS San Raffaele | Conditions: Severe Combined Immunodeficiency Syndrome | Phase 1, Phase 2 | Status: COMPLETED